Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning [NA]
A terminated clinical trial evaluated transcranial magnetic stimulation (rTMS) as a tool to decrease pain and improve functioning in individ…
-
FDA approval · 2022-12-16FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
FDA approved a supplemental application for Suboxone (buprenorphine/naloxone) submitted by Indivior Inc.
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
The FDA approved a supplemental application for buprenorphine hydrochloride under an Abbreviated New Drug Application from PAI Holdings, LLC…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's supplemental application for Buprenorphine HCl and Naloxone HCl (buprenorphine and naloxone).
-
FDA approval · 2022-12-16FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) from Orexo US, Inc., updating i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for a generic buprenorphine and naloxone product from Lannett Company, expanding access to treatment…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product from SpecGx L…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for a buprenorphine and naloxone product from Mylan Pharmaceuticals Inc., enabling continued mar…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for Buprenorphine and Naloxone from Dr. Reddy's Laboratories Inc., indicating an approved supplement…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for a buprenorphine/naloxone product from Rhodes Pharmaceuticals L.P., supporting continued mark…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Mylan Pharmaceuticals' buprenorphine/naloxone product, confirming continued approval for tre…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (INGENUS PHARMACEUTICALS, LLC)
FDA approved a supplemental application for a generic buprenorphine/naloxone product from Ingenus Pharmaceuticals, LLC, enabling its continu…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Hikma Pharmaceuticals USA Inc. to market a buprenorphine generic product under ANDA 078633.
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine and naloxone from Actavis Pharma, Inc., indicating updated labeling for this gener…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Hikma's buprenorphine hydrochloride and naloxone hydrochloride dihydrate, expanding its appr…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Sun Pharmaceutical's buprenorphine/naloxone product. This approval signifies changes to the …
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
The FDA approved a supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product from Acco…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine and naloxone from PAI Holdings/PAI Pharma, indicating an additional regulatory app…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for the generic buprenorphine and naloxone sublingual film from Alvogen Inc., authorizing market aut…
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for a generic buprenorphine and naloxone product manufactured by Dr. Reddy's Laboratories Inc for op…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Comparing Two Training Methods for Opioid Wizard [NA]
A completed clinical trial comparing two training methods related to opioid use disorder/ opioid dependence; results posted in 2022.
-
FDA approval · 2022-12-14FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride submitted by VistaPharm, LLC.
-
FDA approval · 2022-12-13FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for buprenorphine and naloxone from Actavis Pharma, Inc.
-
FDA approval · 2022-12-06FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for buprenorphine and naloxone from Dr. Reddy's Laboratories, enabling a generic product for the tre…
-
FDA approval · 2022-12-06FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for a buprenorphine and naloxone product from Dr. Reddy's Laboratories Inc. for the treatment of opi…